A Hidden Immune Signal Lets H. Pylori Set the Stage for Stomach Cancer

If you have ever tested positive for H. pylori (Helicobacter pylori, a stomach bacterium that colonizes roughly half the people on Earth) and wondered how a quiet, often symptom-free infection could eventually set the stage for cancer, a new mechanistic study gets closer to an answer than before. Working in mice and lab-grown stomach tissue, researchers traced a specific chain of signals, from a bacterial trigger through an immune alarm to a hormone-like messenger, that pushes stomach lining cells into an abnormal, embryo-like growth pattern long associated with the earliest steps toward gastric cancer. The work is entirely preclinical, but it hands scientists a concrete set of molecular switches to test next.

Key takeaways:

• In mice, losing a single growth-regulating signal (BMP) in stomach lining cells was enough, by itself, to flip those cells into an abnormal, embryo-like growth state also seen with H. pylori infection.
• The trigger runs through a relay of signals: an immune messenger called IL-1β activates an enzyme (COX2) in the tissue around the stomach glands, which produces a hormone-like lipid (PGE2) that switches on the growth protein YAP in the lining cells.
• Blocking one receptor in that relay (EP4) in lab-grown stomach tissue significantly cut the abnormal activation back down, pointing to a possible drug target.
• Caveat: all of this is mouse and lab-dish data; human stomach cells carry the same receptor genes, but nobody has shown the same pathway drives this process in a human stomach.

H. Pylori Pushes Stomach Cells Into a Fetal-Like Growth State

A study published in Nature Communications found that H. pylori infection drives stomach lining cells in mice back into a "fetal-like" regenerative state, a pattern of gene activity normally switched off after birth that mirrors the growth program seen in embryonic stomach tissue. Using mice engineered to lack Bmpr1a, the receptor for BMP (bone morphogenetic protein, a signal that normally tells stomach cells to mature and stop dividing) in their stomach lining, the team showed that losing this single brake was enough, on its own, to flip on the same fetal-like program and cause gland overgrowth, even without any infection at all. The signature showed up as activation of YAP (Yes-associated protein, a growth-driving protein that is normally dormant in adult tissue) and a marker called Anxa1, both of which also rose in mice actually infected with H. pylori.

Why a Bacterium Half the World Carries Is Worth Worrying About

H. pylori infection matters because of where it can lead. The World Health Organization has classified H. pylori as a definite, Group 1 cancer-causing agent since 1994, and chronic infection is the strongest known risk factor for gastric adenocarcinoma, the most common form of stomach cancer. Most carriers never develop cancer, but the minority who do typically pass through years of silent tissue remodeling first, exactly the kind of abnormal regeneration this study examines. Anyone managing a diagnosis of chronic gastritis, a prior H. pylori infection, or a family history of gastric cancer has a direct stake in understanding what actually drives that remodeling at the molecular level.

Knockout Mice, Organoids, and a Lab-Grown Tissue Model Pinned Down the Mechanism

To work out how losing BMP signaling triggers this cascade, the researchers combined several mouse and lab-dish systems. In Bmpr1a knockout mice, loss of BMP signaling left epithelial cells unable to dampen inflammatory signaling, so exposure to bacterial molecules (like ADP-heptose, a molecule used in the lab to mimic H. pylori's effects) or other inflammatory triggers caused the cells to pump out proinflammatory chemokines. That recruited immune cells, mainly neutrophils and monocytes/macrophages, into the tissue, and those immune cells released IL-1β, a key inflammatory messenger protein. IL-1β then acted on stromal cells (the supportive tissue surrounding the gastric glands) through a receptor called IL1R1, switching on an enzyme, COX2, that produces PGE2, a hormone-like lipid. PGE2 in turn bound a receptor on the epithelial cells, EP4, and that final step is what switched on YAP and completed the fetal-like reprogramming. The team confirmed the relay directly in gastric assembloids (a 3D lab-dish system combining stomach epithelium with its supporting stromal cells): adding IL-1β increased YAP-active epithelial cells, and blocking the EP4 receptor with a drug-like inhibitor significantly cut that effect back down. This mechanistic work builds on the same lab's earlier finding that H. pylori disrupts BMP signaling in the stomach lining in the first place.

What This Could Mean if You're Managing an H. Pylori History

None of this changes how H. pylori is diagnosed or treated today; standard antibiotic eradication therapy remains the established approach, and this study does not test any new drug in people. What it does offer is a clearer map of why chronic infection, rather than a brief one, appears to matter so much: the longer the IL-1β/COX2/PGE2/YAP relay stays switched on, the longer stomach tissue sits in this abnormal regenerative state. For someone who has had H. pylori, that is one more reason confirmed eradication (a repeat breath or stool test after antibiotics, not just symptom relief) is worth asking a doctor about rather than assuming the infection cleared on its own. It is not, however, a basis for taking anti-inflammatory drugs or any other intervention aimed at this pathway on your own; none of that has been tested as a treatment and the study's own mouse model used genetic knockouts, not drugs, to probe the pathway.

The Big Caveat: Every Finding Here Is From Mice and Lab-Grown Tissue

The clearest limitation is also the most important one: every result described above comes from genetically engineered mice, mouse-derived organoids, and lab-grown assembloids. Human applicability is untested. The researchers did check whether the same molecular players exist in human stomach tissue, by scanning existing human single-cell sequencing data, and found that human gastric stromal cells do express the same IL-1 receptor and COX2/PGE2 pathway genes as the mouse stroma. But that is an expression-pattern match, not proof the same cascade actually drives fetal-like reprogramming in a human stomach. A second limitation is scale: many of the mouse experiments used small per-group sample sizes, around two to six animals per group, though the researchers note the key experiments were independently repeated two to three times with consistent results, which helps offset the small individual group sizes.

What Comes Next: A Druggable Pathway, With an Open Question Attached

Each step in this relay (IL-1β, COX2, PGE2, EP4, YAP) is a known or emerging drug target in other diseases, which is why the authors frame this as a path toward intervention rather than just a mechanism paper. But the pathway's role in the stomach is not simple to act on yet. An earlier mouse study found that giving synthetic PGE2 directly actually prevented H. pylori-driven precancerous lesions, by damping a different, T-cell-driven immune response, which is the opposite of what blocking COX2/PGE2 would do to the YAP pathway described here. Reconciling those two roles for the same molecule, in the same organ, is an open question the authors leave for future work, alongside confirming whether the relay functions the same way in human gastric tissue rather than only mouse models. Separately, YAP itself is already under active study as a drug target in gastric cancer more broadly, which may offer another route in if the upstream IL-1β/COX2/PGE2 signal proves hard to target directly.

Common Questions

Does this mean H. pylori causes cancer through this exact pathway in people? Not yet established. The relay was mapped entirely in mice, mouse organoids, and lab-grown tissue models; human stomach cells carry the same receptor genes, but no one has shown the pathway drives the same reprogramming in a human stomach.

Should I take anti-inflammatory drugs to block this pathway? No. The study did not test any drug treatment in this context, used genetic knockouts rather than medications to probe the pathway, and an earlier mouse study found that boosting the related PGE2 signal, not blocking it, protected against precancerous changes in a different way. Talk to a doctor about standard H. pylori treatment and confirmed eradication testing instead.

What should someone with a current or past H. pylori infection actually do? Confirm the infection actually cleared with a follow-up breath or stool test after antibiotic treatment, since this study's findings underscore why eradicating the bacterium, not just treating symptoms, is what interrupts the chain of events it describes.

References

1. Giulia Beccaceci, Stefanie Müllerke, Hilmar Berger, et al. (2026). Helicobacter pylori triggers gastric mucosal remodeling toward a fetal-like transcriptional program via stromal IL-1β signaling. Nature Communications. https://doi.org/10.1038/s41467-026-77520-1
2. H. Pylori and Cancer Risk Fact Sheet – National Cancer Institute. cancer.gov. https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/h-pylori-fact-sheet
3. Marta Kapalczynska, Manqiang Lin, Jeroen Maertzdorf, et al. (2022). BMP feed-forward loop promotes terminal differentiation in gastric glands and is interrupted by H. pylori-driven inflammation. Nature Communications. https://doi.org/10.1038/s41467-022-29176-w
4. Isabella M. Toller, Iris Hitzler, Ayca Sayi, Anne Mueller (2010). Prostaglandin E2 Prevents Helicobacter-Induced Gastric Preneoplasia and Facilitates Persistent Infection in a Mouse Model. Gastroenterology. https://doi.org/10.1053/j.gastro.2009.12.006
5. Lornella Seeneevassen, Pierre Dubus, Caroline Gronnier, Christine Varon (2022). Hippo in Gastric Cancer: From Signalling to Therapy. Cancers. https://doi.org/10.3390/cancers14092282